Katelyn A O’HAre

Katelyn A O’HAre

Auto-generated profile, based on publicly available information

Katelyn A O’HAre

Rustbelt Center for AIDS Research, Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University School of Medicine , Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in ImmunoHorizons
Verified
Journal Article
Open access
TPTimothy M Pierpont
Timothy M Pierpont
JEJessica Elmore
Jessica Elmore
ARAmie Redko
Amie Redko
OAOrchi Anannya
Orchi Anannya
BIBrian Imbiakha
Brian Imbiakha
AAAvery August
Avery August
Perfluorohexane sulfonate (PFHxS) is a member of the per- and polyfluoroalkyls (PFAS) superfamily of molecules, characterized by their fluorinated carbon chains and use in a wide range of industrial applications. PFHxS and perfluorooctane sulfonate are able to accumulate in the environment and in humans with the approximated serum elimination half-life in the range of several years. More recently, some PFAS compounds have also been suggested as potential immunosuppressants. In this study, we analyze immune cell numbers in mice following 28-d repeated oral exposure to potassium PFHxS at 12, 120, 1,200, and 12,000 ng/kg/d, with resulting serum levels ranging up to ∼1,600 ng/ml, approximating ranges found in the general population and at higher levels in PFAS workers. The immunosuppressant cyclophosphamide was analyzed as a positive control. B cells, T cells, and granulocytes from the bone marrow, liver, spleen, lymph nodes, and thymus were evaluated. We found that at these exposures, there was no effect of PFHxS on major T or B cell populations, macrophages, dendritic cells, basophils, mast cells, eosinophils, neutrophils, or circulating Ab isotypes. By contrast, mice exposed to cyclophosphamide exhibited depletion of several granulocyte and T and B cell populations in the thymus, bone marrow, and spleen, as well as reductions in IgG1, IgG2b, IgG2c, IgG3, IgE, and IgM. These data indicate that exposures of up to 12,000 ng/kg of PFHxS for 28 d do not affect immune cell numbers in naive mice, which provides valuable information for assessing the risks and health influences of exposures to this compound.

6 February 2026 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
MFMichael Freeman
Michael Freeman
WFWendy Fitzgerald
Wendy Fitzgerald
BCBrian M Clagett
Brian M Clagett
KOKatelyn A O’HAre
Katelyn A O’HAre
VJVikhyath Jonnalagadda
Vikhyath Jonnalagadda
KEKristine M Erlandson
Kristine M Erlandson
Background: Little is known about the specific inflammatory networks and immune parameters that drive frailty outcomes in people with HIV (PWH). Methods: Plasma analytes and T-cell phenotypes from PWH without frailty (0 Fried score, n = 60) and with frailty (≥3 Fried score, n = 60) were measured by Luminex assay or flow cytometry. Multiple least-squares linear regression analysis was used to determine the association of each marker with frailty in unadjusted and adjusted models. Spearman correlations were used to determine the association of plasma analytes with T-cell phenotypes. Results: We found that 19 of 75 markers measured in plasma were significantly associated with frailty, most of which are downstream of NF-κB signaling and are senescence-associated secretory phenotype (SASP) components. In frail individuals, the proportions of CD4 and CD8 T cells with a naïve phenotype were significantly reduced, and the proportions of CD4 T cells expressing TIGIT and PD-1 were significantly elevated. Of the frailty-associated analytes, we found that only osteoprotegerin and TNF levels were significantly correlated with percent naïve, TIGIT+, and PD-1+ CD4 T cells among PWH with frailty. Osteoprotegerin levels were negatively correlated with CD4/CD8 T-cell ratio. Conclusions: We found a strong association of the SASP and NF-κB-related inflammation with frailty in PWH. Osteoprotegerin can inhibit osteoclast formation and prevent bone resorption. Low proportion of naïve CD4 T cells and increased TIGIT and PD-1 expression were associated with both osteoprotegerin levels and frailty, suggesting a link between inflammation, T-cell activation, bone health, and frailty in PWH.